Modality
Radioligand
MOA
RAS(ON)i
Target
VEGF
Pathway
Autophagy
Wet AMD
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
~Sep 2017
→ ~Dec 2018
NDA/BLA
~Mar 2019
→ ~Jun 2020
Approved
Sep 2020
→ May 2031
ApprovedCurrent
NCT03467850
2,489 pts·Wet AMD
2021-07→2029-06·Completed
NCT06561627
1,061 pts·Wet AMD
2020-09→2031-05·Not yet recruiting
3,550 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2029-06-083.2y awayPh3 Readout· Wet AMD
2031-05-275.2y awayPh3 Readout· Wet AMD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2029-06-08 · 3.2y away
Wet AMD
Ph3 Readout
2031-05-27 · 5.2y away
Wet AMD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03467850 | Approved | Wet AMD | Completed | 2489 | VA |
| NCT06561627 | Approved | Wet AMD | Not yet recr... | 1061 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |